Clinical characteristics of patients with anti-Jo-1 antibodies: A single center experience

Journal of Clinical Rheumatology

Volumn 15, Issue 5, 2009, Pages 254-255

  Mileti, Linda M ^a   Strek, Mary E ^a   Niewold, Timothy B ^a   Curran, James J ^a   Sweiss, Nadera J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; JO 1 ANTIBODY; PREDNISONE;

AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; FIBROSIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MEDICAL RECORD REVIEW; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ANTIBODIES, ANTINUCLEAR; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMYOSITIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 69549092084     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181b0e910     Document Type: Article

References (14)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-347.
2. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360-374.
3. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459-467.
4. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum. 1995;38:1519-1523.
5. Oddis CV. Idiopathic inflammatory myopathies: a treatment update. Curr Rheum Rep. 2003;5:431-436.
6. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439-2446. (Pubitemid 41117430)
7. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-607. (Pubitemid 40216325)
8. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000. (Pubitemid 24015043)
9. Spath M, Schroder M, Schlotter-Weigel B, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol. 2004;251:859-864. (Pubitemid 39005972)
10. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614-622. (Pubitemid 35461314)
11. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677-685. (Pubitemid 351679543)
12. La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurance of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249-253. (Pubitemid 43879038)
13. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol. 1989;16:479-481.
14. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum. 1988;18:29-37.